Background: Female sexual dysfunction (FSD) defined as the persistent/recurring decrease in sexual desire or arousal, the difficulty/inability to achieve an orgasm, and/or the feeling of pain during sexual intercourse. Therapeutic options available are few pharmacological options in the treatment of FSD. Objective: To study the efficacy of flibanserin and vardenafil on female sexual dysfunction and identify which is the best. Methods: The study was conducted in Gynecology and Obstetrics Department and Dermatology and Venereology Department, Faculty of Medicine, Zagazig University Hospitals during the period from February 2019 to December 2019. Thirty-two married female patients were included in this study. These patients were divided into two groups. Group I included sixteen patients who were treated by vardenafil and group II included the sixteen patients who were treated by flibanserin. Results: The present study showed that there were no statistical significant differences between the studied groups in any of demographic data. In addition, there were no statistical significant differences between the two studied groups in all scores pre-treatment. However, there was statistical significant increase in desire, orgasm and total score among Group II (flibanserin) compared to Group I (vardenafil) post-treatment. Conclusion: Treatment of FSD is multi-factorial. Medications alone do not resolve FSD. Flibanserin is a controversial drug approved for a controversial disorder amid huge controversy. While it may serve as the light in the long search for female sexual problems, which still has a long way to go. Women taking this drug must well be educated about the adverse events associated with this drug and the possible interactions.